May 14th 2024
In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior reduction of treated bleeding episodes.
Steadying the Path of Good Science
November 12th 2018As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?
Navigating the Increasing Complexity of Drug-Biomarker Co-Development
September 10th 2018To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
The Big Apple’s Fresh Start in Biotech
August 7th 2018Though challenges in space and affordability remain, New York City is emerging as a hotspot for biotech incubators, including one unique startup based in the city’s fast-growing innovation center, whose CEO, like many C-suite veterans, made the career leap from the big pharma world to forging new discoveries in medical science.
Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersys
July 10th 2018While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.